Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Long-term efficacy and safety of fosamprenavir plus ritonavir versus lopinavir/ritonavir in combination with abacavir/lamivudine over 144 weeks.

Pulido F, Estrada V, Baril JG, Logue K, Schewe K, Plettenberg A, Duiculescu D, Yau L, Vavro C, Lim ML, Pharo C.

HIV Clin Trials. 2009 Mar-Apr;10(2):76-87. doi: 10.1310/hct1002-76.

PMID:
19487177
3.

[The "induction-maintenance" strategy].

Arribas López JR.

Enferm Infecc Microbiol Clin. 2008 Dec;26 Suppl 16:8-11. Review. Spanish.

PMID:
19572438
4.
5.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
6.

Darunavir: a review of its use in the management of HIV infection in adults.

McKeage K, Perry CM, Keam SJ.

Drugs. 2009;69(4):477-503. doi: 10.2165/00003495-200969040-00007. Review.

PMID:
19323590
7.

Time to HIV-1 RNA suppression below 5 copies/ml during first-line protease inhibitor-based antiretroviral treatment - any impact of residual viremia on treatment success?

Ripamonti D, Hill A, Lauthouwers E, van Delft Y, Moecklinghoff C.

AIDS Rev. 2013 Oct-Dec;15(4):230-6. Review.

PMID:
24322383
8.

[Efficacy of initial antiretroviral therapy based on lopinavir/ritonavir plus 2 nucleoside/nucleotide analogs in patients with human immunodeficiency virus type 1 infection].

Zamora L, Gatell JM.

Enferm Infecc Microbiol Clin. 2014 Nov;32 Suppl 3:2-6. doi: 10.1016/S0213-005X(14)70160-0. Review. Spanish.

PMID:
25542868
9.

Lopinavir/Ritonavir: a review of its use in the management of HIV-1 infection.

Croxtall JD, Perry CM.

Drugs. 2010 Oct 1;70(14):1885-915. doi: 10.2165/11204950-000000000-00000. Review.

PMID:
20836579
10.

[Lopinavir/ritonavir in new initial antiretroviral treatment strategies].

Rolón MJ, Figueroa MI, Sued O, Cahn P.

Enferm Infecc Microbiol Clin. 2014 Nov;32 Suppl 3:7-11. doi: 10.1016/S0213-005X(14)70161-2. Review. Spanish.

PMID:
25542869
11.

Choice of antiretroviral drugs for postexposure prophylaxis for children: a systematic review.

Penazzato M, Dominguez K, Cotton M, Barlow-Mosha L, Ford N.

Clin Infect Dis. 2015 Jun 1;60 Suppl 3:S177-81. doi: 10.1093/cid/civ110. Review.

PMID:
25972500
12.

[Lopinavir/ritonavir in patients with human immunodeficiency virus infection in special situations].

Tasias M, Aldeguer JL.

Enferm Infecc Microbiol Clin. 2014 Nov;32 Suppl 3:18-21. doi: 10.1016/S0213-005X(14)70163-6. Review. Spanish.

PMID:
25542871
13.

Is there a higher risk of CNS adverse events for PI monotherapy versus triple therapy? A review of results from randomized clinical trials.

Powderly W, Hill A, Moecklinghoff C.

HIV Clin Trials. 2014 May-Jun;15(3):79-86. doi: 10.1310/hct1503-79. Review.

PMID:
24947531
14.

Abacavir + dolutegravir + lamivudine for the treatment of HIV.

Comi L, Maggiolo F.

Expert Opin Pharmacother. 2016 Oct;17(15):2097-106. doi: 10.1080/14656566.2016.1232387. Epub 2016 Sep 13. Review.

PMID:
27616133
15.

Efficacy and safety of atazanavir/ritonavir-based antiretroviral therapy for HIV-1 infected subjects: a systematic review and meta-analysis.

Menshawy A, Ismail A, Abushouk AI, Ahmed H, Menshawy E, Elmaraezy A, Gadelkarim M, Abdel-Maboud M, Attia A, Negida A.

Arch Virol. 2017 Mar 30. doi: 10.1007/s00705-017-3346-9. [Epub ahead of print] Review.

PMID:
28361290

Supplemental Content

Support Center